Otonomy

OverviewSuggest Edit

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

TypePublic
Founded2008
HQSan Diego, CA, USMap
Websiteotonomy.com
View Jobs (3)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)49
Job Openings3
Revenue (FY, 2020)$273 K(-54%)
Share Price (Sept 2021)$1.6(+4%)
Cybersecurity ratingAMore

Key People/Management at Otonomy

David A. Weber

David A. Weber

Chief Executive Officer, President and Board Member
Jeffery J. Anderson

Jeffery J. Anderson

Vice President, Clinical Sciences
Carla da Luz Boren

Carla da Luz Boren

General Counsel and Head of Human Resources
Julie D. Burgess

Julie D. Burgess

Vice President, Finance and Administration
Paul E. Cayer

Paul E. Cayer

Chief Financial & Business Officer
David Skarinsky

David Skarinsky

Vice President, Clinical
Show more

Otonomy Office Locations

Otonomy has an office in San Diego
San Diego, CA, US (HQ)
4796 Executive Dr
Show all (1)

Otonomy Financials and Metrics

Otonomy Revenue

Embed Graph
View revenue for all periods
Otonomy's revenue was reported to be $273 k in FY, 2020
USD

Revenue (Q1, 2021)

90.0k

Gross profit (Q1, 2021)

(140.0k)

Gross profit margin (Q1, 2021), %

(155.6%)

Net income (Q1, 2021)

(12.2m)

EBIT (Q1, 2021)

(11.8m)

Market capitalization (14-Sept-2021)

89.5m

Closing stock price (14-Sept-2021)

1.6

Cash (31-Mar-2021)

51.0m

EV

53.6m
Otonomy's current market capitalization is $89.5 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

683.0k1.2m745.0k600.0k273.0k

Revenue growth, %

81%(40%)

Cost of goods sold

1.7m3.1m946.0k912.0k1.2m

Gross profit

(981.0k)(1.9m)(201.0k)(312.0k)(915.0k)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

358.0k326.0k282.0k301.0k123.0k113.0k192.0k190.0k125.0k160.0k10.0k50.0k90.0k

Cost of goods sold

463.0k397.0k290.0k272.0k241.0k162.0k213.0k203.0k220.0k214.0k511.0k189.0k230.0k

Gross profit

(105.0k)(71.0k)(8.0k)29.0k(118.0k)(49.0k)(21.0k)(13.0k)(95.0k)(54.0k)(501.0k)(139.0k)(140.0k)

Gross profit Margin, %

(29%)(22%)(3%)10%(96%)(43%)(11%)(7%)(76%)(34%)(5010%)(278%)(156%)
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.2m18.5m33.6m25.2m30.8m

Accounts Receivable

91.0k107.0k108.0k48.0k

Prepaid Expenses

2.4m2.4m

Inventories

1.4m6.0k227.0k
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

13.7m22.3m16.9m23.2m19.0m21.4m16.3m12.1m16.3m31.0m32.0m54.2m51.0m

Accounts Receivable

178.0k76.0k126.0k133.0k14.0k45.0k14.0k68.0k33.0k

Prepaid Expenses

1.5m3.7m2.2m1.5m2.8m3.0m

Inventories

1.2m1.2m1.2m455.0k
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(110.6m)(90.1m)(50.4m)(44.7m)(44.7m)

Depreciation and Amortization

708.0k1.3m1.2m1.1m1.1m

Inventories

(1.4m)153.0k

Accounts Payable

(2.2m)(398.0k)68.0k127.0k(374.0k)
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(27.1m)(71.3m)(11.4m)(25.0m)(37.5m)(12.0m)(23.7m)(33.7m)(11.8m)(23.2m)(34.1m)(12.2m)

Depreciation and Amortization

923.0k295.0k594.0k892.0k276.0k565.0k854.0k286.0k569.0k843.0k221.0k

Inventories

1.2m1.2m197.0k6.0k

Accounts Payable

212.0k1.3m138.0k1.5m(184.0k)321.0k123.0k837.0k(90.0k)(264.0k)(491.0k)(655.0k)(209.0k)
show all
USDFY, 2016

Revenue/Employee

4.9k

Financial Leverage

1.1 x
Show all financial metrics

Otonomy Operating Metrics

FY, 2016

Patents Issued

88

Patents Pending

115

Phase III Trials Products

2

Products

1
Show all operating metrics

Otonomy Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

Learn more about our premium products
SecurityScorecard logo

Otonomy Online and Social Media Presence

Otonomy's Trends

Embed Graph

Otonomy News and Updates

August 19, 2021

Otonomy Appoints Jill Broadfoot to Board of Directors

SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the appointment of Jill Broadfoot to its board of directors.
August 04, 2021

Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET
July 28, 2021

Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2021 and provide a corporate update at 4:30 p.m. E…
June 15, 2021

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of an expansion study for the Phase 1/2 clinical trial of OTO-413 in patients with speech-i…
May 14, 2021

Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency
May 11, 2021

Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30 p.m. ET
Show more

Otonomy Blogs

May 04, 2021

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update Content Import Tue, 05/04/2021 - 07:30 Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update May 4, 2021 at 7:30 AM EDT This release is a backfill…
September 02, 2020

Otonomy to Participate in Four Upcoming Investor Conferences

Otonomy to Participate in Four Upcoming Investor Conferences Content Import Wed, 09/02/2020 - 07:30 Otonomy to Participate in Four Upcoming Investor Conferences September 2, 2020 at 7:30 AM EDT This release is a backfill from a News Wire General…
July 28, 2020

Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update

Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update Content Import Tue, 07/28/2020 - 16:06 Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update July 28, 2020 at 4:05 PM EDT This release is a back…
July 13, 2020

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Content Import Mon, 07/13/2020 - 16:01 Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Ju…
July 09, 2020

Otonomy Announces Pricing of $60.1 Million Public Offering

SAN DIEGO , July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price to the
July 08, 2020

Otonomy Announces Proposed Public Offering

SAN DIEGO , July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy , Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that it has commenced an underwritten public offering of its common stock.
Show more

 Otonomy Frequently Asked Questions

  • When was Otonomy founded?

    Otonomy was founded in 2008.

  • Who are Otonomy key executives?

    Otonomy's key executives are David A. Weber, Jeffery J. Anderson and Carla da Luz Boren.

  • How many employees does Otonomy have?

    Otonomy has 49 employees.

  • What is Otonomy revenue?

    Latest Otonomy annual revenue is $273 k.

  • What is Otonomy revenue per employee?

    Latest Otonomy revenue per employee is $5.6 k.

  • Who are Otonomy competitors?

    Competitors of Otonomy include Seed Health, BeyondSpring and PPD.

  • Where is Otonomy headquarters?

    Otonomy headquarters is located at 4796 Executive Dr, San Diego.

  • Where are Otonomy offices?

    Otonomy has an office in San Diego.

  • How many offices does Otonomy have?

    Otonomy has 1 office.